159 related articles for article (PubMed ID: 16110016)
1. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
DeMichele A; Aplenc R; Botbyl J; Colligan T; Wray L; Klein-Cabral M; Foulkes A; Gimotty P; Glick J; Weber B; Stadtmauer E; Rebbeck TR
J Clin Oncol; 2005 Aug; 23(24):5552-9. PubMed ID: 16110016
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
Gor PP; Su HI; Gray RJ; Gimotty PA; Horn M; Aplenc R; Vaughan WP; Tallman MS; Rebbeck TR; DeMichele A
Breast Cancer Res; 2010; 12(3):R26. PubMed ID: 20459744
[TBL] [Abstract][Full Text] [Related]
3. GSTT1, GSTM1, and GSTP1 polymorphisms as a prognostic factor in women with breast cancer.
Oliveira AL; Oliveira Rodrigues FF; Dos Santos RE; Rozenowicz RL; Barbosa de Melo M
Genet Mol Res; 2014 Jan; 13(2):2521-30. PubMed ID: 24535908
[TBL] [Abstract][Full Text] [Related]
4. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
Ludovini V; Antognelli C; Rulli A; Foglietta J; Pistola L; Eliana R; Floriani I; Nocentini G; Tofanetti FR; Piattoni S; Minenza E; Talesa VN; Sidoni A; Tonato M; Crinò L; Gori S
BMC Cancer; 2017 Jul; 17(1):502. PubMed ID: 28747156
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
6. The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia.
Barragan E; Collado M; Cervera J; Martin G; Bolufer P; Roman J; Sanz MA
Leuk Res; 2007 Jul; 31(7):947-53. PubMed ID: 17118447
[TBL] [Abstract][Full Text] [Related]
7. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.
Medeiros R; Pereira D; Afonso N; Palmeira C; Faleiro C; Afonso-Lopes C; Freitas-Silva M; Vasconcelos A; Costa S; Osório T; Lopes C
Int J Clin Oncol; 2003 Jun; 8(3):156-61. PubMed ID: 12851839
[TBL] [Abstract][Full Text] [Related]
8. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility and outcomes in muscle invasive bladder cancer patients.
Kang HW; Song PH; Ha YS; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Moon SK; Kim WJ
Eur J Cancer; 2013 Sep; 49(14):3010-9. PubMed ID: 23810248
[TBL] [Abstract][Full Text] [Related]
9. Relevance of GSTM1, GSTT1 and GSTP1 Gene Polymorphism to Breast Cancer Susceptibility in Mizoram Population, Northeast India.
Kimi L; Ghatak S; Yadav RP; Chhuani L; Lallawmzuali D; Pautu JL; Kumar NS
Biochem Genet; 2016 Feb; 54(1):41-9. PubMed ID: 26407578
[TBL] [Abstract][Full Text] [Related]
10. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.
Su HI; Sammel MD; Velders L; Horn M; Stankiewicz C; Matro J; Gracia CR; Green J; DeMichele A
Fertil Steril; 2010 Jul; 94(2):645-54. PubMed ID: 19376514
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J
Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670
[TBL] [Abstract][Full Text] [Related]
12. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.
Chacko P; Joseph T; Mathew BS; Rajan B; Pillai MR
Mutat Res; 2005 Mar; 581(1-2):153-63. PubMed ID: 15725614
[TBL] [Abstract][Full Text] [Related]
13. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
14. Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.
Schilthuizen C; Broyl A; van der Holt B; de Knegt Y; Lokhorst H; Sonneveld P
Haematologica; 2007 Feb; 92(2):277-8. PubMed ID: 17296590
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma.
Khedhaier A; Remadi S; Corbex M; Ahmed SB; Bouaouina N; Mestiri S; Azaiez R; Helal AN; Chouchane L
Br J Cancer; 2003 Oct; 89(8):1502-7. PubMed ID: 14562023
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
17. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
[TBL] [Abstract][Full Text] [Related]
18. CYP1A1, GSTM1 and GSTT1 genetic polymorphisms and gastric cancer risk among Japanese: A nested case-control study within a large-scale population-based prospective study.
Hidaka A; Sasazuki S; Matsuo K; Ito H; Charvat H; Sawada N; Shimazu T; Yamaji T; Iwasaki M; Inoue M; Tsugane S;
Int J Cancer; 2016 Aug; 139(4):759-68. PubMed ID: 27062139
[TBL] [Abstract][Full Text] [Related]
19. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
20. Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk.
Park SK; Yim DS; Yoon KS; Choi IM; Choi JY; Yoo KY; Noh DY; Choe KJ; Ahn SH; Hirvonen A; Kang D
Breast Cancer Res Treat; 2004 Nov; 88(1):55-62. PubMed ID: 15538046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
